PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
MATTER CLOSING MEMORANDUM
CALDERWOOD & HARKNESS LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
TO: Sylvia Hartwell, Billing Partner; Garrett Simmons, Lead Associate; Leila Nazari, Working Associate
FROM: Leonard Cross, Responsible Partner, Tax Department
DATE: March 29, 2024
RE: Matter Closing Memorandum — Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination Defense (TY 2017–2020); Matter No. 1018-00009
CLASSIFICATION: For Internal Firm Use Only — Do Not Distribute Outside Calderwood & Harkness LLP
Right-click to update Table of Contents
I. PURPOSE AND EXECUTIVE SUMMARY
The purpose of this memorandum is to memorialize the closure of Matter 1018-00009 following the execution of an IRS Form 906 Closing Agreement on March 29, 2024, formally resolving the IRS Large Business & International Division's multi-year transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC"), EIN 22-3741856, for tax years 2017, 2018, 2019, and 2020. This memorandum provides a comprehensive record of the engagement from inception to conclusion, including the factual background, the IRS's proposed adjustments, the firm's defense strategy, the settlement terms, the financial implications for the client, and going-forward recommendations. It is intended to serve as the definitive internal record of the matter and to facilitate knowledge management for any future proceedings involving PPC or analogous transfer pricing engagements.
Client. Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on oncology, immunology, and rare-disease therapeutics, with fiscal year 2020 revenue of approximately $6.82 billion and approximately 14,500 global employees.
Primary Client Contacts. Throughout the engagement, our principal points of contact at PPC were as follows:
• Marcus Whitfield, Vice President, Global Tax
• Deborah Staines, General Counsel
• Rajesh Iyer, Chief Financial Officer
• Catherine Falk, Chief Executive Officer
IRS Examination Team. The examination was conducted by the IRS Large Business & International Division, Northeast Transfer Pricing Practice, under Team ID LB&I-NE-TP-2022-00641. The examination team consisted of:
• Gerald Meskill, Supervisory Revenue Agent (Team Manager)
• Patricia Dunleavy, Lead Revenue Agent
• Dr. Alan Washburne, IRS Economist
• Franklin Rosario, Attorney-Advisor, IRS Office of Chief Counsel (Transfer Pricing)
• Donna Hirabayashi, Senior Counsel, IRS Office of Chief Counsel
IRS Appeals. The case was assigned to Appeals Officer Noreen Castañeda following the filing of PPC's Formal Protest in December 2023.
Engagement Duration. The Calderwood & Harkness engagement letter was executed on June 2, 2022. The IRS examination was opened by Letter 2205-A dated May 16, 2022. The examination was formally closed on March 29, 2024, with the execution of the IRS Form 906 Closing Agreement.
Bottom-Line Outcome. The matter was resolved through settlement at IRS Appeals, achieving a total adjustment of $47.6 million across all four tax years, representing 12.51% of the IRS's proposed net adjustment of $380.4 million. All penalties were fully abated. The total cash cost to PPC is approximately $12.84 million, consisting of tax of approximately $10.0 million and estimated interest of approximately $2.84 million. This represents an 86.6% reduction from the IRS's proposed assessment of approximately $95.86 million (comprising tax of approximately $79.88 million plus a substantial valuation misstatement penalty of approximately $15.98 million). Total professional fees incurred across all advisors were approximately $8,325,420 (Calderwood & Harkness LLP: $5,837,420; Whitmore Valuation Group LLC: $2,146,800; Thornbury & Keogh, Chartered Tax Advisors: €312,500, approximately $341,200 at the average exchange rate). The all-in cost to PPC, inclusive of professional fees, settlement tax, and estimated interest, was approximately $21,165,420.
II. ENGAGEMENT OVERVIEW
A. Retention and Staffing
Calderwood & Harkness LLP ("C&H") was retained by Penterra Pharmaceuticals Corp. to defend PPC against the IRS's transfer pricing examination for tax years 2017 through 2020. The engagement letter was executed on June 2, 2022, between Calderwood & Harkness LLP and PPC. Prior to execution, a draft engagement letter was circulated to Marcus Whitfield, Vice President of Global Tax, and Deborah Staines, General Counsel, on May 27, 2022, for review and comment. The executed engagement letter set forth the scope of the firm's representation, fee arrangements, and applicable terms.
On June 8, 2022, IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the Internal Revenue Service, authorizing the following Calderwood & Harkness attorneys to represent PPC before the IRS for tax years 2017 through 2020: Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari.
The scope of the engagement encompassed defense through all phases of the IRS examination, including the preparation and submission of responses to Information Document Requests ("IDRs"), the conduct of functional and economic analyses (in coordination with retained economic experts), the analysis and response to the Notice of Proposed Adjustment ("NOPA"), the preparation and filing of a Formal Protest, and full representation before IRS Appeals through final resolution of the examination.
The Calderwood & Harkness team was staffed as follows throughout the engagement:
• Leonard Cross, Responsible Partner — Overall strategic direction and supervision of the matter; lead attorney for Appeals representation; primary client relationship management; all significant communications with IRS examination and Appeals teams.
• Sylvia Hartwell, Billing Partner — Client management and billing oversight; quality review of all major deliverables, including the Formal Protest and economic analysis submissions; participation in the Appeals conference.
• Garrett Simmons, Lead Associate — Day-to-day management of IDR responses; coordination of economic analyses with Whitmore Valuation Group; preparation of the NOPA analysis memorandum; principal drafter of the Formal Protest; preparation of post-settlement memoranda, including amended return filing instructions.
• Leila Nazari, Working Associate — Legal research and preparation of research memoranda; management of document production and privilege log maintenance; coordination with Thornbury & Keogh on Irish tax and substance matters; analysis of ancillary matters, including credit facility covenants, state tax impact, and GILTI/BEAT implications.
At the time of engagement, the estimated fee range for Calderwood & Harkness's services through Appeals resolution was $4.5 million to $7.0 million. As discussed in Section VIII below, the firm's actual fees of $5,837,420 fell within this estimated range.
B. Expert Engagement — Whitmore Valuation Group LLC
To support the firm's legal analysis and advice to PPC on the economic dimensions of the transfer pricing examination, Calderwood & Harkness retained Whitmore Valuation Group LLC ("WVG") under a Kovel engagement letter, executed on June 20, 2022. WVG's principal office is located at 200 Ashbury Asset Advisors, Suite 700, Boston, Massachusetts 02109. The engagement was structured under the Kovel doctrine to preserve the protections of attorney-client privilege over communications between WVG and C&H made for the purpose of enabling C&H to render legal advice to PPC. The Kovel engagement was assigned internal reference number 1018-00009-KV.
The lead economist for the engagement was Dr. Helena Vasquez, Managing Director at WVG, who directed all economic analyses and served as the firm's primary expert witness at the Appeals conference. Dr. Vasquez was supported by Dr. Rohan Chakrabarti, Senior Director, who led the benchmarking and comparable analysis workstreams. WVG billed at a blended rate of $650 per hour across the engagement.
The deliverables produced by WVG during the course of the engagement included the following:
• A comprehensive functional analysis documenting the functions performed, assets used, and risks assumed by PPC, PBI, and PMI in connection with the controlled transactions under examination.
• A Comparable Uncontrolled Transaction ("CUT") benchmarking study analyzing arm's-length royalty rates for pharmaceutical intangible property licenses.
• A Comparable Profits Method ("CPM") / Transactional Net Margin Method ("TNMM") analysis testing PBI's profitability against a set of comparable entities.
• A Platform Contribution Transaction ("PCT") valuation using the income method (Discounted cash flow analysis) to assess the arm's-length value of PBI's buy-in payment.
• A technical memorandum on discount rate and weighted average cost of capital ("WACC") methodology, supporting a 9.8% WACC and critiquing the IRS economist's 7.2% rate.
• A rebuttal memorandum challenging the IRS economist's (Dr. Alan Washburne) methodology, comparable selection, discount rate assumptions, and projected revenue growth rates.
C. Coordination with Other Advisors
Throughout the examination, Calderwood & Harkness coordinated with two other advisory firms retained by PPC and its affiliates.
Crestfield & Associates LLP. Crestfield & Associates LLP ("Crestfield"), located at 1200 Avenue of the Americas, New York, New York 10036, served as PPC's independent auditor and the preparer of PPC's federal income tax returns (Forms 1120) for tax years 2017 through 2020. Crestfield was also the original preparer of PPC's contemporaneous transfer pricing documentation for all four years under examination, which had been prepared to satisfy the penalty protection standards of IRC § 6662(e). The Crestfield engagement was led by Martin Ogilvy, CPA (Engagement Partner) and Susan Lam, CPA (Transfer Pricing Partner). C&H coordinated extensively with Crestfield throughout the examination for the purpose of obtaining return data, transfer pricing documentation workpapers, and supporting schedules necessary for IDR responses and the defense of PPC's reported positions.
Thornbury & Keogh, Chartered Tax Advisors. Thornbury & Keogh ("T&K"), located at 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland, served as the Irish tax advisors to Penterra Biopharma International DAC ("PBI") and Penterra Manufacturing Ireland Ltd. ("PMI"). The T&K engagement was led by Ciarán Thornbury (Lead Partner). C&H coordinated with T&K on dual-jurisdiction aspects of the examination, including PBI substance documentation, Irish Revenue filings, the Knowledge Development box ("KDB") claims at the 6.25% rate, and the potential Irish tax impact of U.S. settlement positions. T&K's total fees for the engagement were €312,500, which translated to approximately $341,200 at the average exchange rate of approximately $1.092 per euro over the engagement period.
III. BACKGROUND — CLIENT STRUCTURE AND TRANSFER PRICING POSITIONS
A. Corporate Structure
The relevant corporate structure for purposes of the transfer pricing examination is as follows:
Penterra Pharmaceuticals Corp. ("PPC") — The U.S. parent entity. PPC is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals globally. PPC's business is focused on specialty pharmaceuticals and biotechnology, with principal therapeutic areas in oncology, immunology, and rare-disease therapeutics. PPC conducts substantially all of its research and development activities at its U.S. facilities and is the owner and developer of the core pharmaceutical IP portfolio at issue in the examination.
Penterra Holdings Luxembourg S.à r.l. ("PHL") — An intermediate holding entity organized under the laws of Luxembourg, registered with the Registre de Commerce et des Sociétés under Number B 168452. PHL's registered office is at 14, rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for U.S. federal income tax purposes and served as an intermediary holding company in the group structure.
Penterra Biopharma International DAC ("PBI") — An Irish designated activity company and the principal IP-holding and commercial entity for PPC's non-Americas operations. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference number is 3218764T, and the entity's Managing Director is Aidan Naughton. PBI is the counterparty to the cost-sharing arrangement and the legacy IP license agreement at the center of the examination.
Penterra Manufacturing Ireland Ltd. ("PMI") — An Irish private limited company serving as the contract manufacturer of PPC's oncology and immunology biologics for non-Americas markets. PMI is located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, and is registered with the Companies Registration Office under CRO Number 512347. PMI employed approximately 620 individuals and manufactured products under a cost-plus arrangement with PBI (cost plus 8%).
PBI is the entity of central importance to the examination. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's employee headcount grew from 52 at the time of its establishment in 2012 to 185 by the end of the period under examination. PBI was responsible for the non-Americas commercialization of PPC products and was subject to the standard Irish corporation tax rate of 12.5% on trading income. Beginning with fiscal year 2016, PBI also claimed the Knowledge Development box rate of 6.25% on qualifying intellectual property income. PBI maintained approximately 18,000 square feet of office space at Sandyford Business Park in Dublin and conducted its principal banking through Glenmore Bank Ireland plc.
B. Key Products
The IRS examination focused on the transfer pricing associated with PPC's three principal pharmaceutical products, each of which generated significant revenue both globally and in the non-Americas territories served by PBI:
Veritaxol was PPC's flagship product and one of the highest-revenue oncology drugs globally, driving the majority of the value at issue in the transfer pricing examination. Imvara was a significant contributor to both global and non-Americas revenue, and Cerulon, while smaller in absolute revenue terms, was a high-margin rare-disease therapy that contributed to the valuation questions surrounding the PCT and the cost-sharing arrangement.
C. Cost-Sharing Arrangement ("CSA")
PBI was incorporated on March 15, 2012, and the qualified cost-sharing arrangement between PPC and PBI was executed effective July 1, 2012. The CSA governed the development and exploitation of PPC's pharmaceutical intellectual property portfolio outside the Americas territory (defined as North America, Central America, South America, and the Caribbean).
Under the CSA, PBI acquired the rights to develop and exploit the covered IP portfolio in the non-Americas territory in exchange for two principal payments:
1. A platform contribution transaction ("PCT") payment of $312 million, paid as a lump sum by PBI to PPC on July 1, 2012, representing a buy-in to the pre-existing IP portfolio, which consisted primarily of clinical-stage and approved oncology compounds.
2. Ongoing cost-sharing payments representing PBI's share of the annual intangible development costs ("Coss") in the shared R&D cost pool.
PPC's reported cost-sharing ratios for the tax years under examination, which were determined based on reasonably anticipated benefit ("RAB") projections, were as follows:
The gradual increase in PBI's cost-sharing percentage over the examination period reflected the projected growth in non-Americas revenue relative to Americas revenue, consistent with PPC's RAB methodology. The cost-sharing ratios and the underlying RAB projections were a central point of contention in the IRS examination.
D. Legacy IP Royalty Arrangement
In addition to the CSA covering post-2012 IP development, PBI licensed certain pre-2012 vintage legacy compounds from PPC under a separate intercompany license agreement. Under this agreement, PBI paid PPC a royalty of 4.5% of net sales attributable to the non-Americas territory for these legacy products.
The legacy compound royalty income for the tax years under examination was as follows:
The declining trajectory of legacy compound revenue over the examination period reflected the natural life-cycle dynamics of older pharmaceutical products and the increasing share of revenue attributable to newer compounds covered by the CSA. The 4.5% royalty rate was a significant area of dispute, as the IRS proposed more than doubling the rate to 11.0%.
E. PBI's Economic Substance and DEMPE Functions
A critical dimension of the defense, and one that ultimately contributed substantially to the favorable settlement outcome, was the demonstration of PBI's genuine economic substance and its performance of meaningful Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions in connection with the covered intellectual property.
PBI employed regulatory, medical-affairs, commercial-strategy, and supply-chain personnel at its Dublin offices. PBI bore the market risk for commercialization in the non-Americas territories and made key commercial decisions with respect to pricing, market entry strategy, and the selection of distribution partners across 68 country markets. The PBI board of directors held 42 board meetings in Dublin during the 2017–2020 examination period, consisting of regularly scheduled quarterly meetings as well as special sessions convened to address material business decisions. PBI incurred cumulative regulatory expenditures of €47.2 million during the examination period for regulatory submissions and approvals in non-Americas markets.
In the early stages of the engagement, Calderwood & Harkness conducted detailed interviews with 12 key PBI employees during August and September 2022 to document their roles, responsibilities, and decision-making authority. These interviews provided the evidentiary foundation for the functional analysis and substance defense that were presented to the IRS examination team and subsequently to IRS Appeals.
IV. EXAMINATION HISTORY AND TIMELINE
A. Examination Opening and IDR Phase
The IRS opened its examination of PPC's transfer pricing positions on May 16, 2022, with the issuance of an initial contact letter (Letter 2205-A) from the LB&I Northeast Transfer Pricing Practice. The examination was assigned Team ID LB&I-NE-TP-2022-00641 and was supervised by Supervisory Revenue Agent Gerald Meskill.
Calderwood & Harkness's engagement letter was executed on June 2, 2022, six days after the draft engagement letter had been circulated to Marcus Whitfield and Deborah Staines. On June 8, 2022, IRS Form 2848 was filed, authorizing the C&H team to represent PPC. On June 20, 2022, the Kovel engagement letter with Whitmore Valuation Group was executed to secure privileged economic support.
On June 22, 2022, the opening conference with the IRS examination team was confirmed, and the conference was held on June 28, 2022. Attendees at the opening conference included Leonard Cross and Garrett Simmons from Calderwood & Harkness, Marcus Whitfield from PPC, and Supervisory Revenue Agent Gerald Meskill and Lead Revenue Agent Patricia Dunleavy from the IRS. During the conference, the IRS outlined the scope of the examination, which centered on PPC's transfer pricing with its Irish affiliates, and the parties discussed the anticipated IDR schedule and procedures for document production.
The Information Document Request phase spanned from June 2022 through September 2023. During this period, Lead Revenue Agent Patricia Dunleavy issued a total of 47 IDRs, each requiring the compilation, review (for privilege), and production of significant volumes of documents and data. The IDR responses were coordinated principally by Garrett Simmons, with document production managed by Leila Nazari, and with substantial input from PPC's internal tax team led by Marcus Whitfield and supporting data from Crestfield & Associates.
The key IDR responses covered the following subject areas, among others:
• IDR 1: Corporate structure and organizational charts for PPC, PHL, PBI, and PMI.
• IDR 2: The CSA agreement and all amendments thereto.
• IDR 3: The legacy IP license agreement between PPC and PBI.
• IDR 4: Contemporaneous transfer pricing documentation for all four tax years.
• IDR 5: PCT valuation workpapers, including all assumptions, projections, and discount rate analyses.
• IDR 6: R&D cost pool composition and allocation methodology documentation.
• IDR 7: PBI financial statements and Irish tax returns for all examination years.
• IDR 8: PBI personnel records, headcount data, and organizational structure.
• IDR 9: PBI board of directors minutes for all meetings during 2017–2020.
• IDR 10: The PMI manufacturing agreement and cost-plus documentation.
• IDR 11: Product revenue data disaggregated by territory and product line.
• IDR 12: PBI office lease agreements and documentation of physical presence in Dublin.
• IDR 15: Regulatory expenditure records and submissions in non-Americas markets.
• IDR 18: Distribution agreements for non-Americas territories.
• IDR 22: Banking records and Glenmore Bank Ireland plc account statements for PBI.
• IDR 25: Comparable license agreements relied upon in transfer pricing analyses.
• IDR 30: Knowledge Development box claims and supporting documentation.
• IDR 35: Documentation of intercompany pricing decisions and approval processes.
• IDR 40: Forms 5471 (Information Return of U.S. Persons with Respect to Certain Foreign Corporations) for PBI and PMI.
• IDR 44: Capital expenditure records for PBI and PMI.
• IDR 47 (final): Supplemental documentation including compensation records, travel records, and additional personnel data. This final IDR was issued on September 29, 2023.
Several notable procedural events occurred during the IDR phase. On September 20, 2022, Calderwood & Harkness submitted an extension request for IDR 14, which involved complex data compilation requirements. On February 15, 2023, the firm lodged a formal objection to the scope of IDR 26, asserting that the request was overbroad and not reasonably related to the transfer pricing issues under examination. Following negotiation, a narrowed version of IDR 26 was agreed upon. On May 10, 2023, Calderwood & Harkness requested a mid-examination conference pursuant to IRS procedures to discuss the examination's direction and the IRS team's preliminary positions.
Throughout the IDR phase, Calderwood & Harkness maintained a comprehensive privilege log documenting all documents withheld from production on grounds of attorney-client privilege and attorney work-product protection. The privilege protocol, established by memorandum dated June 10, 2022, governed the identification, logging, and withholding of privileged materials, including communications protected under the Kovel arrangement with Whitmore Valuation Group.
With respect to statute of limitations management, IRS Forms 872 (Consent to Extend the Time to Assess Tax) were executed for tax years 2017 and 2018, extending the statute of limitations for assessment through December 31, 2024. Tax years 2019 and 2020 remained within the normal three-year assessment period at the time the examination was opened and throughout the examination's duration.
B. IRS Economist Involvement
The IRS examination team engaged Dr. Alan Washburne from the IRS Transfer Pricing Practice as its economist on the matter. Dr. Washburne conducted an independent economic analysis of PPC's transfer pricing positions, including the CSA cost-sharing ratios, the legacy IP royalty rate, and the PCT valuation. On August 15, 2023, Calderwood & Harkness (Cross, Simmons) and Whitmore Valuation Group (Dr. Vasquez) participated in a meeting with Dr. Washburne to discuss his economic methodology, his selection of comparables, and his discount rate assumptions. This meeting provided critical insight into the IRS's likely economic positions and informed the development of our rebuttal strategy.
C. IRS Chief Counsel Involvement
The IRS Office of Chief Counsel assigned Franklin Rosario, Attorney-Advisor (Transfer Pricing), to provide legal support to the examination team. The Senior Counsel overseeing the matter was Donna Hirabayashi. On September 20, 2023, Calderwood & Harkness (Cross, Simmons) participated in a call with Rosario to discuss legal positions on CSA compliance under Treasury Regulation § 1.482-7, the economic substance of PBI as an IP owner and CSA participant, and related legal theories. This call confirmed the IRS's intention to challenge both the economic terms of the controlled transactions and the underlying substance of PBI's role.
D. Mid-Examination Conference
On May 25, 2023, a mid-examination conference was held at Calderwood & Harkness's request. The conference provided an opportunity to discuss the IRS's preliminary positions, the status and scope of remaining IDRs, and the anticipated timeline for the issuance of any proposed adjustments. The conference served to clarify several areas of the IRS's focus and enabled the defense team to refine its strategy in advance of the NOPA.
E. Notice of Proposed Adjustment (NOPA) — October 12, 2023
On October 12, 2023, the IRS examination team issued a Notice of Proposed Adjustment covering all four tax years under examination. The NOPA set forth proposed adjustments to PPC's taxable income totaling $380.4 million (net of correlative offsets) and asserted a substantial valuation misstatement penalty under IRC § 6662(e) of approximately $15.98 million.
Upon receipt of the NOPA, Garrett Simmons and Leila Nazari prepared a detailed analysis memorandum, dated October 20, 2023, dissecting each component of the proposed adjustment, evaluating the IRS's legal and economic positions, and identifying points of vulnerability in the IRS's analysis. Leonard Cross notified Marcus Whitfield of the NOPA by email on October 15, 2023, providing an initial summary and assessment, and a more detailed discussion followed upon completion of the analysis memorandum.
F. 30-Day Letter — November 8, 2023
The IRS issued its 30-Day Letter on November 8, 2023, formally providing PPC with the opportunity to file a Protest and request consideration of the proposed adjustments by IRS Appeals. Leonard Cross communicated the procedural options available to PPC — including the right to file a Protest, to request a conference with IRS Appeals, or to agree to the proposed adjustments — to Marcus Whitfield on November 9, 2023. PPC determined to exercise its right to protest.
Calderwood & Harkness submitted a request for an extension of the deadline to file the Formal Protest. The request was granted, and the filing deadline was extended to December 22, 2023.
G. Formal Protest — Filed December 22, 2023
The preparation of the Formal Protest was the single most substantial written deliverable of the engagement. Three drafts were prepared internally before the Protest was finalized:
• Version 1 (December 5, 2023): Initial draft prepared by Simmons and Nazari, incorporating all factual arguments, legal analysis, and economic evidence.
• Version 2 (December 12, 2023): Revised draft incorporating comments from Cross and Hartwell, with refined legal arguments and restructured presentation of economic evidence.
• Version 3 (December 16, 2023): Final internal draft circulated to PPC for client review.
Marcus Whitfield provided comments on Version 3 on December 19, 2023. PPC approved the Protest for filing with minor factual revisions, and the Formal Protest was filed with the IRS on December 22, 2023.
The Formal Protest was accompanied by five exhibits:
• Exhibit A: Corporate structure chart depicting PPC, PHL, PBI, and PMI.
• Exhibit B: Summary of the CSA, including the effective date of July 1, 2012, the PCT payment of $312 million, and the cost-sharing percentages for each examination year.
• Exhibit C: Summary of economic analyses, including: CUT analysis (interquartile range of 3.1%–6.8%, median 4.4%); CPM/TNMM analysis (22 comparables); PCT DCF valuation (arm's-length range of $278 million to $361 million).
• Exhibit D: PBI economic substance evidence, including 185 employees, 42 board meetings held in Dublin, €47.2 million in cumulative regulatory expenditures, 18,000 square feet of Dublin office space, and commercial operations across 68 non-Americas country markets.
• Exhibit E: Penalty protection and contemporaneous documentation under IRC § 6662(e)(3)(B).
The substantive arguments set forth in the Protest addressed the following issues:
• The arm's-length nature of PPC's transfer pricing under IRC § 482 and Treasury Regulations §§ 1.482-4, 1.482-7, and 1.482-1(d).
• The arm's-length character of the 4.5% legacy IP royalty rate, supported by the CUT benchmarking analysis.
• The arm's-length nature of the CSA cost-sharing ratios, supported by the RAB methodology and the CPM/TNMM analysis.
• The arm's-length nature of the $312 million PCT payment, supported by the income method/DCF valuation.
• PBI's economic substance and the performance of meaningful DEMPE functions in Ireland.
• The reasonable-cause defense and penalty protection based on contemporaneous documentation and reliance on qualified advisors.
H. IRS Appeals Phase
In January 2024, the case was assigned to Appeals Officer Noreen Castañeda. On January 10, 2024, Calderwood & Harkness sent a letter to Castañeda requesting the scheduling of an Appeals conference and proposing dates in late February 2024.
In advance of the conference, a pre-conference memorandum was prepared on February 15, 2024, consolidating all key arguments, evidence, and potential settlement frameworks. Additionally, witness preparation memoranda were prepared for Marcus Whitfield and Dr. Helena Vasquez, who would be participating in the conference and presenting testimony regarding PPC's transfer pricing positions and the economic analyses, respectively.
The Appeals conference was held in person on February 28, 2024, at the IRS Appeals Office in Manhattan. The attendees were as follows:
• Calderwood & Harkness: Leonard Cross, Sylvia Hartwell, Garrett Simmons
• PPC: Marcus Whitfield, Deborah Staines
• Whitmore Valuation Group: Dr. Helena Vasquez
• IRS Appeals: Appeals Officer Noreen Castañeda
During the conference, Calderwood & Harkness delivered a comprehensive oral presentation covering the case overview, PPC's positions on each disputed issue, the factual background of PPC's corporate structure and controlled transactions, the economic analyses prepared by Whitmore Valuation Group, the evidence of PBI's economic substance, the legal arguments under IRC § 482 and applicable regulations, and a proposed resolution framework. Dr. Vasquez presented and defended the economic analyses, and Marcus Whitfield provided factual testimony regarding PBI's operations and commercial decision-making.
On March 1, 2024, Garrett Simmons prepared a post-conference summary memorandum documenting the substance of the conference, the Appeals Officer's questions and responses, and an assessment of the likely trajectory of settlement discussions. Leonard Cross debriefed Marcus Whitfield, Deborah Staines, and Rajesh Iyer by email on the same date.
On March 8, 2024, Calderwood & Harkness submitted a supplemental submission to Appeals providing additional comparable license agreements and updated benchmarking data that had been requested by Appeals Officer Castañeda during the conference.
I. Settlement and Closing — March 2024
On March 15, 2024, Appeals Officer Castañeda communicated a settlement offer to Calderwood & Harkness. The proposed settlement called for a total adjustment of $47.6 million across all four tax years, with full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty.
On March 18, 2024, Leonard Cross and Sylvia Hartwell prepared a settlement offer analysis memorandum addressed to Marcus Whitfield, Deborah Staines, and Rajesh Iyer. The memorandum set forth a detailed analysis of the settlement terms, a comparison of the settlement to the potential outcomes of continued litigation (including the risks and costs of Tax Court proceedings), and a recommendation that PPC accept the settlement offer.
On March 19, 2024, Leonard Cross communicated a detailed financial impact summary to CFO Rajesh Iyer, quantifying the tax, interest, and total cash cost of the proposed settlement, as well as the implications for PPC's financial statements and reserves.
On March 21, 2024, Marcus Whitfield confirmed that PPC management — including CFO Rajesh Iyer and CEO Catherine Falk — had approved the acceptance of the settlement terms.
On March 22, 2024, Leonard Cross sent a formal letter to Appeals Officer Castañeda on behalf of PPC accepting the settlement.
On March 29, 2024, the IRS Form 906 Closing Agreement was executed, bearing the signatures of Marcus Whitfield on behalf of PPC and the authorized representative of IRS Appeals. With the execution of the Closing Agreement, the examination of PPC for tax years 2017 through 2020 was formally closed.
V. IRS's PROPOSED ADJUSTMENTS — SUMMARY
The IRS's proposed adjustments, as set forth in the NOPA issued on October 12, 2023, are summarized below.
A. CSA Cost-Sharing Ratio Adjustments
The IRS proposed increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year. The IRS's position was that PPC's reasonably anticipated benefit projections understated the value attributable to U.S.-source contributions to the covered intangibles, thereby understating PBI's appropriate share of the intangible development cost pool. The specific proposed adjustments were as follows:
Subtotal — CSA cost-sharing ratio adjustments: $235.01 million.
B. Legacy IP Royalty Rate Adjustments
The IRS proposed increasing the royalty rate on the legacy IP license from PPC's reported rate of 4.5% to 11.0% of net sales for the non-Americas territory, an increase of 6.5 percentage points. The IRS based this proposed adjustment on CUT data derived from third-party pharmaceutical licensing agreements, which the IRS economist asserted reflected arm's-length rates for comparable intangible property. The specific proposed adjustments were:
Subtotal — Legacy IP royalty rate adjustments: $188.04 million.
C. PCT Undervaluation Issue
The IRS asserted that PBI's PCT payment of $312 million, made on July 1, 2012, undervalued the pre-existing pharmaceutical IP portfolio by approximately $540 million. The IRS's valuation, prepared by Dr. Alan Washburne, utilized the income method with a WACC of 7.2% and revenue projections that assumed higher growth rates than those used by PPC's advisors, arriving at a concluded PCT value of approximately $852 million.
Because the 2012 tax year was outside the scope of the examination years (2017–2020), the IRS did not propose a direct adjustment to the 2012 PCT payment. Instead, the IRS used the asserted PCT undervaluation as support for its recharacterization of the ongoing CSA cost-sharing ratios and royalty rates for the examination years, arguing that the artificially low buy-in price was indicative of a broader pattern of underpricing PBI's obligations to PPC.
D. Economic Substance Challenge
The IRS asserted in part that PBI lacked sufficient economic substance to be respected as a genuine IP owner and CSA participant. The IRS's position was that key DEMPE functions — particularly the development, enhancement, and protection of the pharmaceutical IP — were performed predominantly in the United States by PPC personnel, and that PBI's role was limited to routine distribution and commercial functions that did not justify the allocation of residual IP-related profits to Ireland.
E. Correlative Offset
The examination team allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing adjustments and the legacy IP royalty adjustments, recognizing that certain of the proposed increases in the royalty rate and the cost-sharing ratios would result in overlapping adjustments to the same income streams.
F. Net Proposed Adjustment
The IRS's net proposed adjustment was calculated as follows:
CSA cost-sharing adjustments: $235.01 million
Legacy IP royalty adjustments: $188.04 million
Less correlative offset: ($42.65 million)
Net proposed adjustment: $380.40 million
G. Proposed Penalty
The IRS asserted a substantial valuation misstatement penalty under IRC § 6662(e) at a rate of 20% on the tax attributable to the proposed § 482 allocation. The penalty calculation was as follows:
Net proposed adjustment: $380.4 million
Applicable tax rate: 21%
Tax on proposed adjustment: $79.88 million
Substantial valuation misstatement penalty (20%): $15.98 million (rounded)
The IRS reserved the right to assert the gross valuation misstatement penalty under IRC § 6662(h) at a rate of 40% but did not ultimately assert that penalty.
VI. DEFENSE STRATEGY AND KEY DELIVERABLES — SUMMARY
A. Legal Framework
The defense strategy was grounded in the following legal authorities:
• IRC § 482 — Allocation of income and deductions among controlled entities to clearly reflect income.
• IRC § 367(d) — Outbound transfers of intangible property to related foreign corporations.
• Treasury Regulation § 1.482-4 — Methods to determine taxable income in connection with transfers of intangible property, including the comparable uncontrolled transaction method.
• Treasury Regulation § 1.482-7 — Qualified cost-sharing arrangements, including PCT valuation and cost-sharing ratio determination.
• Treasury Regulation § 1.482-1(d) — The arm's-length standard and the best method rule.
• IRC § 6662(e) — The substantial valuation misstatement penalty applicable to § 482 transfer pricing adjustments, and the penalty protection available under IRC § 6662(e)(3)(B) for taxpayers with qualifying contemporaneous documentation.
• Revenue Procedure 2015-41 — Procedures governing IRS Appeals conferences.
• OECD Transfer Pricing Guidelines (2017 and 2022 revisions) — Cited as persuasive authority, particularly with respect to the DEMPE framework, the application of the arm's-length principle, and the analysis of cost-contribution arrangements.
Key case law relied upon in the defense included:
• Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), relating to the inclusion of stock-based compensation in cost-sharing pools.
• Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112 (and subsequent proceedings), relating to the application of the comparable uncontrolled transaction method and the selection of comparables in the medical device and pharmaceutical context.
• Hollowell & Co. v. Commissioner, T.C. Memo. 2017-25, relating to cost-sharing buy-in valuations and the income method.